JP2025503015A - アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 - Google Patents

アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 Download PDF

Info

Publication number
JP2025503015A
JP2025503015A JP2024543009A JP2024543009A JP2025503015A JP 2025503015 A JP2025503015 A JP 2025503015A JP 2024543009 A JP2024543009 A JP 2024543009A JP 2024543009 A JP2024543009 A JP 2024543009A JP 2025503015 A JP2025503015 A JP 2025503015A
Authority
JP
Japan
Prior art keywords
subject
beta
cyp11β2
serum
hydroxylase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503015A5 (https=
Inventor
ロッドマン，デイビッド
テイラー スリングズビー，ブライアン
コングレトン，ジョン
シミズ，ヒデトシ
オオタ，ヨシヤス
オリハシ，マドリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mineralys Therapeutics Inc
Original Assignee
Mineralys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mineralys Therapeutics Inc filed Critical Mineralys Therapeutics Inc
Publication of JP2025503015A publication Critical patent/JP2025503015A/ja
Publication of JP2025503015A5 publication Critical patent/JP2025503015A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024543009A 2022-01-19 2023-01-19 アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法 Pending JP2025503015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263300967P 2022-01-19 2022-01-19
US63/300,967 2022-01-19
US202263400301P 2022-08-23 2022-08-23
US63/400,301 2022-08-23
PCT/IB2023/050444 WO2023139506A1 (en) 2022-01-19 2023-01-19 Methods of treating hypertension by periodic suppression of aldosterone synthase

Publications (2)

Publication Number Publication Date
JP2025503015A true JP2025503015A (ja) 2025-01-30
JP2025503015A5 JP2025503015A5 (https=) 2026-01-26

Family

ID=87347916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543009A Pending JP2025503015A (ja) 2022-01-19 2023-01-19 アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法

Country Status (7)

Country Link
US (1) US20250099475A1 (https=)
EP (1) EP4466021A4 (https=)
JP (1) JP2025503015A (https=)
KR (1) KR20240140102A (https=)
CA (1) CA3240577A1 (https=)
TW (1) TW202339758A (https=)
WO (1) WO2023139506A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025527706A (ja) * 2022-08-23 2025-08-22 ミネラリス・セラピューティクス・インコーポレイテッド 肥満対象における高血圧を治療する方法
CA3265668A1 (en) * 2022-08-23 2024-02-29 Mineralys Therapeutics, Inc. METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886117C (en) * 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
JP2023546970A (ja) * 2020-10-26 2023-11-08 ミネラリス・セラピューティクス・インコーポレイテッド 高血圧のためのｃｙｐ１１ｂ２ベータヒドロキシラーゼ阻害剤

Also Published As

Publication number Publication date
CA3240577A1 (en) 2023-07-27
EP4466021A4 (en) 2026-01-14
US20250099475A1 (en) 2025-03-27
WO2023139506A1 (en) 2023-07-27
EP4466021A1 (en) 2024-11-27
TW202339758A (zh) 2023-10-16
KR20240140102A (ko) 2024-09-24

Similar Documents

Publication Publication Date Title
Luther et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II–induced cardiac, renal, and vascular injury
US9387249B2 (en) Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
JP2002529405A (ja) 心臓血管系疾患による発病率及び死亡率減少のためのアンギオテンシン変換酵素阻害薬及びアルドステロン拮抗薬の併用療法
US9216221B2 (en) Medicament and method of diagnosis for treating subclinical Cushing's syndrome
JP7814368B2 (ja) 慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
JP2025503015A (ja) アルドステロン合成酵素を周期的に抑制することによる高血圧症の治療方法
Glicklich et al. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists
Patel et al. The emerging role of aldosterone synthase inhibitors in overcoming renin–angiotensin–aldosterone system therapy limitations: a narrative review
Croom et al. Eplerenone: a review of its use in essential hypertension
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
CN110785168A (zh) 用于预防或治疗猫的全身性疾病的血管收缩素ii受体拮抗剂
Merlo et al. Aldosterone synthase inhibitors across the translational spectrum: Mechanistic foundations and emerging clinical applications
US20260053812A1 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
US20260053811A1 (en) Methods of treating hypertension in obese subjects
Elliott et al. Pharmacology of antihypertensive drugs
Delyani Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
TW202519234A (zh) 以洛倫德羅斯塔(lorundrostat)及二或多種降血壓藥物之組合治療高血壓之方法
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
GB2503396A (en) Treatment of subclinical Cushing's syndrome and/or incidentaloma
Epstein in the Management of Hypertension
Rossi et al. THE ALDOSTERONE RENIN RATIO BASED ON THE? PLASMA RENIN ACTIVITY AND THE DIRECT RENIN ASSAY FOR DIAGNOSING ALDOSTERONE-PRODUCING ADENOMA: PP. 24.471

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260116